Skip to main content
Premium Trial:

Request an Annual Quote

NY Genome Center to Use $3M Sloan Grant to Recruit Scientists

NEW YORK (GenomeWeb News) – The New York Genome Center said today that it plans to use a new $3 million grant from the Alfred P. Sloan Foundation to begin recruiting bioinformatics and sequencing specialists.

NYGC, a non-profit, New York City-based research institute that includes a number of members and partners from the biomedical research, life sciences tools, clinical care, and pharmaceutical communities, is raising $125 million in investments to fund its genome sequencing and bioinformatics efforts.

Illumina and Roche are NYGC's lead corporate partners, and its institutional founding members include The Jackson Laboratory; Cold Spring Harbor Laboratory; Columbia University; Mount Sinai Medical Center; New York University/NYU School of Medicine; Memorial Sloan-Kettering Cancer Center; Rockefeller University, and regional clinical care hospitals.

NYGC aims to be one of the largest genome research facilities in North America, with a staff of 350 researchers, although it has not yet announced a decision on where in New York City its permanent home, expected to be around 120,000 square feet, will be located.

Its facilities will include a service center for sequencing, bioinformatics, and internal and collaborative research, a CLIA lab, an innovation center for testing new technologies, a commercialization and data mining center, and a training component.

In February, NYGC said in its first large-scale project it will work with Illumina and the Feinstein Institute for Medical Research to sequence and analyze 1,000 human genomes over four years in a study focused on Alzheimer's disease.

That study aims to generate knowledge about Alzheimer's risk genes, define the molecular pathways for neuronal degeneration, and support development of early detection tools and targeted treatments.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.